Juniper Pharmaceuticals Inc Watch

from 8-K 90 pages Agreement and Plan of Merger by and Among: Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals, Inc. Dated as of July 2, 2018

from SC TO-C 90 pages Agreement and Plan of Merger by and Among: Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals, Inc. Dated as of July 2, 2018

from 10-K 10 pages Amendment No. 2 to Purchase and Collaboration Agreement

from 8-K 60 pages Dated September 2013 Share Purchase Agreement Between the Sellers and Columbia Laboratories, Inc. and Molecular Profiles Limited

from 8-K 144 pages Purchase and Collaboration Agreement by and Among Columbia Laboratories, Inc., Coventry Acquisition, Inc. and Watson Pharmaceuticals, Inc. Dated as of March 3, 2010

from DEFA14A 144 pages Purchase and Collaboration Agreement by and Among Columbia Laboratories, Inc., Coventry Acquisition, Inc. and Watson Pharmaceuticals, Inc. Dated as of March 3, 2010

from SC 13D/A ~20 pages Agreement Dated as of Dec. 30, 1998

from SC 13D/A ~5 pages Plan of reorganization, merger, acquisition or similar

from SC 13G/A 1 page <page> 10 of 11 Exhibit B Joint Filing Agreement Pursuant to Rule 13d-1(f) (1) This Agreement Is Made Pursuant to Rule 13d-1(f)(1) Under the Securities Exchange Act of 1934, as Amended (The "Act") by and Among the Parties Listed Below, Each Referred to Herein as a "Joint Filer." the Joint Filers Agree That a Statement of Beneficial Ownership as Required by Section 13(d) of the Act and the Rules Thereunder May Be Filed on Each of Their Behalf on Schedule 13d or Schedule 13g, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings. the Joint Filers States That They Each Satisfy the Requirements for Making a Joint Filing Under Rule 13d-1. Dated: February 2, 1998 /S/ Jeffrey S. Lambert - Mark E. Strome Strome Susskind Investment Management, L.P. by Ssco, Inc., Its General Partner By: /S/ Jeffrey S. Lambert Jeffrey S. Lambert, Chief Financial Officer Ssco, Inc. By: /S/ Jeffrey S. Lambert Jeffrey S. Lambert, Chief Financial Officer